{"result": "Here is a comprehensive summary of the data:\n\nThe \"DECT TRIAL\" is a study that investigated the use of neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab in the treatment of breast cancer. Specifically, the trial involved the administration of docetaxel, epirubicin, and cyclophosphamide in a sequential manner, with trastuzumab given concurrently, as a neoadjuvant treatment for breast cancer.", "input": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we the have full context.\n\n#######\n-Data-\nEntities: \"\\\"DECT TRIAL\\\"\"\nDescription List: [\"\\\"DECT Trial is a study on neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.\\\"\", \"\\\"DECT Trial is an event that investigated the use of neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab in the treatment of breast cancer.\\\"\"]\n#######\nOutput:\n", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 500, "n": null}}